Literature DB >> 23430946

Homocysteine and erythrocyte sedimentation rate correlate with cerebrovascular disease in fabry disease.

R Cheung1, D O Sillence, M C Tchan.   

Abstract

BACKGROUND: Cerebrovascular disease (CVD) is a common clinical problem in Fabry disease; however, expression of this disease manifestation is not uniform and risk factors for its development are not well studied. A number of common CVD risk factors are known in the general population, and these may also play a role in the development of CVD in Fabry disease. AIM: To evaluate the potential associations between various risk factors and CVD in patients with Fabry disease. METHODS AND
RESULTS: Thirty-two Fabry disease patients were studied, with 15 having evidence of CVD. T-tests were used to compare the positive and negative CVD groups and logistic regression was used to look for correlations with CVD history. CVD-positive patients were older (49.73 vs. 37.59 years, p<0.001) and had worse renal function (GFR 61.53 vs. 96.61 mL/min/1.73 m(2), p < 0.005), higher homocysteine (17.79 vs. 10.53 μmol/L, p < 0.05) and erythrocyte sedimentation rate (ESR) levels (23.8 vs. 7.64 mm/h, p < 0.001), and elevated Mainz Severity Score Index (MSSI) scores (23.8 vs. 11.8, p < 0.001). Correlations were found between age (odds ratio (OR) 1.11), DTPA glomerular filtration rate (OR 0.95), homocysteine concentration (OR 1.22), ESR (OR 1.16) and the MSSI (OR 1.19) scores with a positive CVD history (all p < 0.05).
CONCLUSION: Elevated homocysteine and ESR are independent risk factors for CVD in Fabry disease. This finding adds to our ability to predict those patients with Fabry disease who are at a higher risk of developing CVD, and may be an aid in deciding which patients should have primary CVD prevention therapies.

Entities:  

Year:  2012        PMID: 23430946      PMCID: PMC3565641          DOI: 10.1007/8904_2011_123

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  21 in total

1.  Homocysteine and stroke.

Authors:  Graeme J Hankey; John W Eikelboom
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

2.  Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's disease.

Authors:  S Fedi; F Gensini; A M Gori; R Abbate; W Borsini
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

Review 3.  Magnetic resonance imaging changes in Fabry disease.

Authors:  Lionel Ginsberg; Renzo Manara; Alan R Valentine; Brian Kendall; Alessandro P Burlina
Journal:  Acta Paediatr Suppl       Date:  2006-04

4.  Erythrocyte sedimentation rate as a marker of inflammation and ongoing coagulation in stroke and transient ischaemic attack.

Authors:  J E Swartz; B F Jacobson; M D Connor; P L Bernstein; V U Fritz
Journal:  S Afr Med J       Date:  2005-08

5.  Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

Authors:  Arndt Rolfs; Tobias Böttcher; Marlies Zschiesche; Peter Morris; Bryan Winchester; Peter Bauer; Uwe Walter; Eilhard Mix; Mathias Löhr; Klaus Harzer; Ulf Strauss; Jens Pahnke; Annette Grossmann; Reiner Benecke
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

Review 6.  The kidney and homocysteine metabolism.

Authors:  Allon N Friedman; Andrew G Bostom; Jacob Selhub; Andrew S Levey; Irwin H Rosenberg
Journal:  J Am Soc Nephrol       Date:  2001-10       Impact factor: 10.121

7.  Natural history of the cerebrovascular complications of Fabry disease.

Authors:  A Mehta; L Ginsberg
Journal:  Acta Paediatr Suppl       Date:  2005-03

Review 8.  Fabry disease: a review of current management strategies.

Authors:  A Mehta; M Beck; F Eyskens; C Feliciani; I Kantola; U Ramaswami; A Rolfs; A Rivera; S Waldek; D P Germain
Journal:  QJM       Date:  2010-07-21

9.  Early prediction of stroke severity. Role of the erythrocyte sedimentation rate.

Authors:  A Chamorro; N Vila; C Ascaso; A Saiz; J Montalvo; P Alonso; E Tolosa
Journal:  Stroke       Date:  1995-04       Impact factor: 7.914

10.  White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions.

Authors:  David F Moore; Gheona Altarescu; W Craig Barker; Nicholas J Patronas; Peter Herscovitch; Raphael Schiffmann
Journal:  Brain Res Bull       Date:  2003-12-30       Impact factor: 4.077

View more
  1 in total

1.  Erythrocyte Sedimentation Rate Measurement Using as a Rapid Alternative to the Westergren Method.

Authors:  Reza Hashemi; Alireza Majidi; Hassan Motamed; Afshin Amini; Fares Najari; Ali Tabatabaey
Journal:  Emerg (Tehran)       Date:  2015
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.